BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Eileen Mary BoyleCody AshbyRuslana G TytarenkoShayu DeshpandeHongwei WangYan WangAdam RosenthalJeffrey SawyerErming TianErin FlyntAntje HoeringSarah K JohnsonMichael W RutherfordChristopher P WardellMichael A BauerCharles DumontetThierry FaconSharmilan ThanendrarajanCarolina D SchinkeMaurizio ZangariFrits van RheeBart BarlogieDavid CairnsGraham JacksonAnjan ThakurtaFaith E DaviesGareth J MorganBrian A WalkerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Overall, these data highlight the importance of mutational screening to better understand newly diagnosed multiple myeloma and may lead to patient-specific mutation-driven treatment approaches.